Bevacizumab biosimilar(Eirgenix)

贝伐珠单抗生物类似药（台康生技）

Report date: 2022/03/16 13:30:58

Base Information

Drug NameBevacizumab biosimilar(Eirgenix)

Drug Alias Name贝伐珠单抗生物仿制药（台康生技）贝伐单抗生物仿制药（台康生技）贝伐单抗生物类似药（台康生技）贝伐人源化单抗生物仿制药（台康生技）贝伐珠单抗生物类似药（台康生技） +[7]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar

Mechanisms of ActionVascular endothelial growth factor A inhibitors

TargetsVascular endothelial growth factor A

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryTaiwan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesEirgenix Inc

China Registration ClassN/A

Active CompaniesEirgenix Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

ATC CodeN/A